Effect of vitamin D supplementation on assisted reproduction technology (ART) outcomes and underlying biological mechanisms: protocol of a randomized clinical controlled trial. The &quot;supplementation of vitamin D and reproductive outcome&quot; (SUNDRO) study by A. Paffoni et al.
STUDY PROTOCOL Open Access
Effect of vitamin D supplementation on
assisted reproduction technology (ART)
outcomes and underlying biological
mechanisms: protocol of a randomized
clinical controlled trial. The
“supplementation of vitamin D and
reproductive outcome” (SUNDRO) study
Alessio Paffoni1, Edgardo Somigliana1,2* , Veronica Sarais3, Stefania Ferrari1, Marco Reschini1, Sofia Makieva4,
Enrico Papaleo3 and Paola Viganò4
Abstract
Background: Vitamin D plays an important role in human physiology and pathology. The receptor for vitamin D
regulates 0.5–5% of the human genome. Accordingly, vitamin D insufficiency has been shown to increase the risk
of several diseases. In recent years, based on growing evidence, on a role of vitamin D has been also postulated in
reproductive health both in animals and humans, especially in female fertility female fertility. In vitro fertilization success
was shown to be higher in women with appropriate reserves of vitamin D. However a causal relation has not
been demonstrated and randomized controlled trials testing the effectiveness of vitamin D supplementation
in IVF are warranted.
Methods: This is a multicenter randomized double blinded placebo controlled study aimed at determining the benefits
of vitamin D [25(OH)D] supplementation in improving clinical pregnancy rate in women undergoing IVF. Eligible women
with a serum level of 25-hydroxyvitamin D [25(OH)D] < 30 ng/ml will be randomized. Recruited women will be
given the drug (either 600,000 IU of 25(OH) D or placebo in a single oral administration) at the time of randomization.
Two centres will participate and the sample size (700 women) is foreseen to be equally distributed between the two.
Patients will be treated according to standard IVF protocols.
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Discussion: The primary aim of the study is the cumulative clinical pregnancy rate per oocyte retrieval. Clinical pregnancy
is defined as the presence of at least one intrauterine gestational sac with viable foetus at first ultrasound assessment (3
weeks after a positive human chorionic gonadotropin [hCG] assessment). Secondary outcomes include: 1) clinical and
embryological variables; 2) oocyte and endometrium quality at a molecular level. To investigate this latter aspect, samples
of cumulus cells, follicular and endometrial fluids will be obtained from a subgroup of 50 age-matched good-prognosis
cases and controls.
Trial registration: The protocol was included in EudraCT on 22nd September 2015 with the registration number assigned
‘2015-004233-27’; it was submitted through the database of the Italian “Osservatorio Nazionale della Sperimentazione
Clinica (OsSC)” - (National Monitoring Centre of Clinical Trials) to the National Competent Authority on 8th March 2016
and approved on 23rd June 2016.
Keywords: IVF, Infertility, Vitamin D, 25(OH)D, Pregnancy rate, Cumulus cells, Endometrium, Oocyte quality, Follicular fluid
Background
Vitamin D plays an important role in human physiology
and pathology. The activation of the vitamin D receptor
(VDR) may regulate directly and/or indirectly the expres-
sion of a very large number of genes (0.5–5% of the total
human genome). Accordingly, vitamin D insufficiency has
been shown to increase the risk of several diseases includ-
ing cancers, auto-immune diseases, infections and preg-
nancy complications [1, 2].
In recent years, a role of vitamin D has been also pos-
tulated in reproductive health. VDR is expressed in the
ovary, the endometrium and the myometrium [3]. More-
over, vitamin D has been shown to influence female
fertility potential in animals and humans [4, 5]. In vitro
fertilization (IVF) success was demonstrated to be higher
in women with appropriate reserves of vitamin D [6]. In
a recent contribution from our group, we detected an
adjusted odds ratio (a-OR) (adjusted for age, ethnicity,
BMI, parity, duration of infertility, number of retrieved
oocytes, number of transferred embryos, and study
period) of 2.15 [95% confidence interval (CI): 1.23–3.77]
for clinical pregnancy rate in women with vitamin D >
20 ng/ml compared to those with vitamin D < 20 ng/ml.
A similar figure was observed when considering the im-
plantation rate. Of note, this beneficial effect was even
more evident when using a threshold of 30 ng/ml [7].
The large body of evidence available in animal models
and data from in vitro studies in women strongly favour
a causal relation, but evidence from RCTs is required to
definitely support a role for vitamin D in influencing the
chances of pregnancy. To date, only a small RCT has
been published and no benefits emerged [8]. However,
the study was insufficiently powered to draw definite
conclusions (in total 117 women). Moreover, only women
scheduled for frozen embryo transfer were included.
Exploring the mechanisms at the basis of the beneficial
effects of vitamin D could also be relevant and may open
new avenues of research. To date, there are few appealing
findings but the scenario is incomplete, especially from
interventional studies. Biological evidence from RCTs
could conversely provide crucial insights on the role of
vitamin D in influencing oocytes quality or endometrial
receptivity.
Oocytes cannot be directly tested for molecular analyses.
However, the evaluation of the cumulus and granulosa
cells of the ovarian follicle could indirectly reveal the qual-
ity of the corresponding oocytes. The gene expression
profile of cumulus-oocyte-complexes has been suggested
to predict which embryos have the best chance of
implanting in the uterus. In particular, the expression of
COX20, BMP15 and GDF9 has been associated with the
establishment of pregnancy or live birth. Other possible
potential genes of interest but with less consistency among
studies include GREM1, HAS2, VCAN, PTGS [9, 10].
Endometrial samples can conversely be obtained prior
to initiate the IVF cycle and can thus be directly studied
without interfering with the procedure. Of interest here
is that the endometrium and the early pregnancy de-
cidua also express VDR and could be other important
targets of vitamin D. In a previous study from our group,
vitamin D was shown to modulate the expression of
genes important for embryo receptivity and to interact
with the local cytokines in human endometrial cells [11].
In the present study the following hypotheses will be
tested: 1) 25-hydroxyvitamin D [25(OH)D] deficiency
negatively affects pregnancy rates in IVF cycles with an
effect mediated through endometrial receptivity and/or
oocyte embryo quality; 2) Vitamin D supplementation
and restoration of adequate vitamin D levels may actu-
ally improve the prognosis of infertile women undergo-
ing IVF procedures. The absolute magnitude of the
benefit deemed to be clinically relevant in terms of
cumulative clinical pregnancy rate is considered 10%
(from 20 to 30%); 3) The molecular profiles of endomet-
rium, follicular fluid and cumulus cells are modified in
vitamin D-supplemented women with respect to molecules
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known to be associated with IVF outcomes and embryo
implantation process.
Methods
The study has been designed according to the CON-
SORT methodology.
Aim
The present trial is aimed at determining the benefits of
vitamin D supplementation in improving cumulative
clinical pregnancy rate in women undergoing IVF. In
particular, the three main aims of the study are as
follows:
Aim 1: To determine the potential benefits of vitamin
D supplementation in improving cumulative clinical
pregnancy rate in women undergoing IVF.
Aim 2: To investigate whether vitamin D
supplementation might improve clinical and
embryological variables such as: number of cancelled
cycles, number of available oocytes, number of good
quality embryos, units of FSH administered per
retrieved oocyte, implantation rate of transferred
embryos.
Aim 3: To investigate the effect of vitamin D
supplementation on oocyte and endometrium quality at
a molecular level through a comparative analysis
between treated and untreated patients based on the
analysis of cumulus cells, follicular and endometrial
fluids.
Setting
This is a multicenter randomized superiority double
blinded placebo controlled clinical trial with parallel
groups and allocation 1:1.
Two Italian academic infertility units will be involved:
– IRCCS Fondazione Ca’ Granda, Ospedale Maggiore
Policlinico, Milan, Italy.
– IRCCS Ospedale San Raffaele, Milan, Italy.
Participants
Inclusion criteria of women will be as follows: indication
to IVF, age 18–39 years, less than 3 previous IVF attempts,
body mass index (BMI) 18–25 kg/m2.
Exclusion criteria will be as follows: patients with anti-
mullerian hormone serum level < 0.5 ng/ml, IVF cycle
using frozen embryos/oocytes, vitamin D contraindica-
tions/side effects for consumption of vitamin D (high
blood calcium levels or conditions that can lead to high
calcium levels such as sarcoidosis, tuberculosis, parathy-
roid disease).
Eligible women will be informed on the study design
and those agreeing to participate will sign an informed
consent and will provide a blood sample for 25(OH) D
assessment. Those with a serum level < 30 ng/ml will be
randomized.
A CONSORT flow diagram of the study protocol is
provided as an additional figure (see Additional file 1).
Interventions
Experimental design aim 1
Recruited women will be given the drug (either 600,000
IU of 25-OH-vitamin D or placebo in a single oral admin-
istration) at the time of randomization, thus 2–12 weeks
prior to oocyte retrieval and managed according to a stan-
dardized clinical protocol of ovarian stimulation with
in vitro fertilization (fresh cycle). Administration of the
drug/placebo will be performed by the physician in order
to guarantee a compete adherence to the protocol. No
dose changes are foreseen. Patients will be asked to avoid
further consumption of vitamin D after randomization.
Women whose cycle will be cancelled will not be
excluded (intention to treat analysis). A specific software
will establish the randomization list. Sun exposure dur-
ing the study period will be recorded but it will not be a
reason for drop-out. Serum 25-OH-Vitamin D will be
reassessed at the time of hCG administration or, if the
cycle will be cancelled, at the time of the decision to
interrupt the treatment. The quantitative detection of
total serum 25(OH) D levels will be performed using a
commercially available kit based on a chemiluminescence
technology (DiaSorin) with intra- and interassay coeffi-
cients of variations equal to 10 and 15%, respectively.
Patients will be treated according to standard IVF pro-
tocols as described elsewhere [12, 13]: since neither the
clinicians nor the recruited women will be aware about
vitamin D dosage, clinical management of ovarian stimu-
lation will not be conditioned by the study.
In case of supernumerary oocytes or embryos deriving
from the fresh cycle, the subsequent embryo transfer using
thawed embryos or oocytes will be considered for the
study outcome if performed within 4months from oocyte
retrieval and 25(OH) D serum levels will be reassessed.
Serum hCG assessment to detect pregnancy will be per-
formed at + 14/+ 16 days after hCG administration. If
positive, women will undergo a transvaginal sonography 3
weeks later.
Clinical pregnancy (primary outcome) is defined as the
presence of at least one intrauterine gestational sac with
viable foetus.
Dates of the study: 27/06/2016–26/06/2019
A schedule of enrolment, interventions and assess-
ments of the study protocol is reported in Fig. 1.
Experimental design aim 2
In order to investigate whether vitamin D supplementa-
tion might improve clinical and embryological parameters,
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we will use our electronic dataset to compare with appro-
priate statistical tests all of the variables that are routinely
collected in IVF cycles. The main variables that we will
consider in order to discover possible effects of vitamin D
supplementation on the clinical outcome of the IVF cycle
are: rate of cancelled cycles, number of available oocytes,
units of FSH administered per retrieved oocyte (they are
related to the rate of appropriate response of the patients
to the stimulation protocol), number of good quality
embryos on the day of embryo transfer as evaluated
according to the Istanbul Consensus (it is related with the
quality of gametes) [14], implantation rate of transferred
embryos (it is related to the quality of embryos and endo-
metrium), delivery rate and obstetric outcomes.
Experimental design aim 3
A subgroup (n = 50) of good-prognosis cases and con-
trols will be recruited among randomized patients for
collection and analysis of biological samples as described
below.
Fig. 1 Schedule of enrolment, interventions and assessments of the SUNDRO trial
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Luteinized granulosa cell gene expression analysis
Human luteinized granulosa cells (GC) from placebo-
and vitamin D- supplemented patient groups will be
isolated from the discarded follicular fluid post oocyte
retrieval according to standard protocols [15]. Briefly,
cells in follicular fluid will be isolated by initial centrifu-
gation of the pool of follicular fluid (2000×g for 10 min)
followed by gradient separation at density of 1.077 g/mL
(Lymphoprep™, STEMCELL Technologies, Vancouver,
Canada). Following the gradient centrifugation (1700×g
for 20 min), three layers will emerge: a top layer contain-
ing the follicular fluid, a bottom layer containing eryth-
rocytes and the middle layer containing mononuclear
cells. The mononuclear middle layer will be collected
and supplemented with 3 ml of RPMI 1640 medium
containing 10% fetal bovine serum. To eliminate the
macrophages, the mononuclear cell suspension will be
incubated in a Petri plate, at 37 °C for 15 min. It is
expected that, while macrophages will adhere to the
plastic during this time frame, luteinized GCs and lym-
phocytes will not. An additional step to separate GCs
from lymphocytes will be performed by maintaining the
cell suspension for 24 h at 37 °C under standard culture
conditions. Due to their physical properties, lympho-
cytes, in contrast to GCs, cannot attach to plastic, thus,
allowing an effective segregation of the two cell types.
GCs will be lysed using the RLT buffer (QIAGEN) and
total RNA will be sentd for RNAseq analysis. TruSeq
Stranded Total RNA Library Prep Kit will be used for
library preparation and sequenced on an Illumina
HiSeq2500 Rapid Run System, generating pair-end 50
base-pair reads (140M reads on average per sample).
Transcript abundance will be estimated with Kallisto [16]
and differentially expressed (DE) genes will be identified
using DeSeq2 R package [17] and a corrected p-value <
0.05. The DE genes that will emerge from RNAseq
analysis between placebo and vitamin D-supplemented
groups, will be validated with RT-PCR using SYBR green
system, QIAGEN pre-validated, ready-to-use primer sets
and QIAGEN real-time PCR cycler, the Rotor-Gene Q. A
new cohort of samples will be employed for the validation.
Western blotting analysis will be used to confirm the
changes in gene expression at the protein level.
Follicular fluid content BMP-15 and GDF-9 are cur-
rently regarded as the best candidate molecules respon-
sible for oocyte regulation of cumulus cell expansion
during ovulation. Follicular samples from both groups of
women will be retrieved via transvaginal route under
ultrasound guidance. Follicular fluids will be centrifuged
at 1000×g for 10 min to remove cellular components;
the clear supernatant will be divided into aliquots and
frozen at − 80 °C until further use. Prior to processing,
the follicular fluids will be centrifuged and filtered on
Millipore filter to remove precipitates. A chemilumines-
cent assay will be used to compare BMP-15, GDF-9 and
25(OH) D levels in follicular fluid of women treated or
not with vitamin D supplementation.
Endometrial secretion pattern Endometrial secretions
from both groups of women treated or not with vitamin
D supplementation will be aspirated using a catheter
during the secretory phase of the menstrual cycle prior
to frozen embryo transfer: a multiplex immunoassay
will be performed to compare the cytokine profile.
Interleukin (IL)-1ß, IL-10, IL-12, IL-15, IL-17, tumor
necrosis factor (TNF)-α, eotaxin, glycodelin A, granulocyte
colony-stimulating factor, monocyte chemotactic protein-1,
vascular endothelial growth factor, interferon-gamma will
be analysed given their known involvement in human em-
bryo implantation.
Data collection and analysis
An electronic dataset will be filled (SPSS ver. 20, IBM).
All data will be recorded with paper case report forms
and entered electronically at both participating sites
using a common dataset. Original study forms will be
stored in numerical order and stored in a secure and
accessible place for 30 years after study completion. A
biostatistician will perform quality control before data
analysis, including check for double data entry and range
for data values. Missing data will be included in the ana-
lysis using specific modern imputation methods.
Statistically significant differences will be determined
using Fisher’s exact test, chi-squared test, Student’s t test
or the Wilcoxon test, as appropriate.
An interim analysis (315 randomized completed cycles)
of clinical pregnancy rates will be performed in order to
highlight unforeseen or higher-than-expected effects of
vitamin D supplementation. According to the Haybittle–
Peto boundary rule, the statistical significance for deciding
to stop the trial is set to p-value < 0.001 [18]. Results of
the interim analysis will be available to all medical and la-
boratory staff. The steering committee decides on the con-
tinuation of the trial and will report to the involved ethics
committees.
In accordance with national guidelines, the main out-
come will be collected for every woman in order to
complete their clinical charts. Since the main outcome is
the clinical pregnancy rate as (defined as the presence of
at least one intrauterine gestational sac with viable
foetus), it has to be noted that its evaluation is highly
standardized and fully objective. Moreover, according to
legal requirements and standard clinical protocols, sec-
ondary outcomes related to the evolution of pregnancies
will be easily collected through usual methods and re-
minders for contacting patients.
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Given the study design, protocol adherence is foreseen
to be complete. However, data will be analysed accord-
ing to the “intention to treat” analysis.
Since the clinical trial is designed as minimal risk a
formal committee for data monitoring is not foreseen.
Electronic monitoring of the datasets will be performed
by two independent physicians every 3 months during re-
cruitment focussing on: completeness of the data, eligibil-
ity criteria, date of randomization, treatment assignment,
adverse events and endpoints, signed informed consent.
Sample size calculation
The sample size was calculated according to Kane [19]
based on the following assumptions:
1) the primary outcome is the cumulative clinical
pregnancy rate (CPR) per started cycle; 2) expected CPR
in the deficient population 20% [7], 3) expected CPR in
the supplemented population 30% [7], 4) expected pro-
portion of women with insufficient serum vitamin D (<
30 ng/ml): 90% [20], 5) Type I and II errors of 0.05 and
0.20, respectively. Under these assumptions, a sample
size of 300 randomized women per arm will allow us to
detect with sufficient statistical power (p < 0.05) an abso-
lute difference ≥ 10% in the CPR rate between the two
groups using the chi-squared test.
Considering that 10% of recruited women are expected
to have serum vitamin D levels ≥30 ng/ml (therefore
they will not be randomized) and considering a dropout
rate of 5%, it has been decided to recruit 700 women to
reach the number of 600 required subjects. The full for-
mula used for sample size calculation is provided as an
additional figure (see Additional file 2).
Randomization
Randomization will be organized centrally by UOC
Farmacia of the Fondazione IRCCS Ospedale Maggiore
Policlinico. The allocation sequence will be computer-
generated and hidden from the participants as well as
from the physicians and biologists involved in the clin-
ical management of the patients. The allocation ratio will
be 1:1. Randomization list will be stratified for the two
participating centres. Since the random list has not other
stratification, the allocation sequence is considered un-
predictable and no restrictions are planned in order to
reduce predictability.
Blinding
All patients, all caregivers and embryologists at the clinical
departments will be blinded to trial intervention alloca-
tion. This is possible because ampoules of drug/placebo
will be prepared and coded in a undistinguishable way by
the local central pharmacy of the Fondazione IRCCS Ca′
Granda according to a computer generated random list.
The pharmacy will reveal the content of administered am-
poule only after cycle completion.
The allocation sequence will be implemented through
administration of anonymized ampoules in the progres-
sive order they are coded by the pharmacy.
The progress of the study will be periodically moni-
tored by an external monitor in order to verify the strict-
ness of the data management. The medical doctors
evaluating the main outcome will also be blinded to the
trial intervention allocation. Unblinding will be possible
after the embryo transfer procedure. In case of adverse
effects of vitamin D supplementation, as reported by
participating women, the care giver of the patient can
obtain information on the participant’s allocated inter-
vention asking to the principal investigator who will ask
the pharmacy using a specific module.
Consent
Women eligible for the study will be referred by care
providers to a member of the research team who will de-
scribe the informed consent process. Details of the study
will be explained to patients, including its main aims,
procedures, temporal commitment, possible discomforts
and risks, benefits. Recruitment will be on a voluntary
basis with the right to withdraw from the study at any
time; moreover, women will be informed that the deci-
sion to join the study protocol will not affect their future
treatments. Volunteers will sign the informed consent
after giving them the opportunity to put questions and
enough time to consider their participation.
Confidentiality
Recruited patients will be assigned anonymous codes
and data analysis will be performed on anonymized data-
sets. Patient data collected during the study protocol will
be treated in accordance with the Italian 196/2003 Data
Protection Act. Electronic datasets will be accessed
through a personal password; paper documentation will
be accessible only to study investigators. Study data will
be kept for at least 10 years after publication of study
results.
Discussion
For the most part, vitamin D is derived from the conver-
sion of pro-vitamin D under the essential effect of solar
ultraviolets. This particular mean of actually satisfying
our needs represents an important concern. The mutated
habits of humans in Western Worlds is not compatible
with an adequate exposure to sunlight and thus hamper
the provision of sufficient vitamin D [2].
The effect of vitamin D supplementation in women
belonging to infertile couples has been insufficiently ex-
plored yet, although several groups have highlighted
better chances of pregnancy in women replete for serum
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vitamin D [6]. Therefore, the hypothesis that vitamin D
supplementation could improve IVF results deserves fur-
ther consideration.
The present study can potentially influence the clinical
practice of infertility treatment. Vitamin D insufficiency
can be simply overcome. Supplementation with vitamin
D is economic, simple and effective and would represent
an innovative and simple adjuvant treatment of IVF with
the potential additional benefit of improving the chances
of natural conception. Of further relevance here is that
vitamin D supplementation is free of relevant side effects.
Dosage of supplementation was based on previous
data showing that a single 600.000 IU dose of cholecal-
ciferol is able to rapidly increase serum 25(OH) D levels
and to maintain adequate levels up to 90 days after
administration in young subjects, including patients with
severe vitamin D depletion. The proposed dosage is in-
deed considered safe since it gives peak levels well below
the widely accepted toxic blood levels of 200 ng/ml [21,
22]. Of note, the single dose administered in-office by
the physician guarantees a total adherence to treatment.
However, given the lack of causal relationship between
vitamin D levels and IVF outcomes and the risk of
excessive vitamin D serum levels, patients will be asked
to avoid further consumption of vitamin D after
randomization. Moreover, at a molecular level, our ana-
lysis can provide preliminary data on reproductive cells
that can be influenced by circulating vitamin D levels
(endometrium, follicle, oocyte cumulus-oocyte complex).
Whether the effect of vitamin D in human reproduction
is mediated at ovarian, endometrial or both levels repre-
sents a matter of controversy. According to our pro-
spective cross-sectional study aiming at investigating
IVF outcomes in women with deficient 25(OH) D level,
the number of top quality embryos and, as a consequence,
the rate of women reaching the stage of blastocyst transfer
was higher in women with sufficient levels of serum
25(OH)D. The chances of embryo implantation were also
enhanced supporting the idea that the impact of the com-
pound might be exerted in both the reproductive tissues
[7]. Disentangling the potential role of vitamin D in the
endometrium is particularly relevant given the key role of
uterine factors in determining the outcome of IVF treat-
ment, the significant gaps in our knowledge of mecha-
nisms underlying endometrial-embryo asynchrony and
most of all, the lack of relevant modifiers of endometrial
receptivity status [23]. Also of particular note, there is
growing and consistent evidence that vitamin D supple-
mentation may improve birth outcomes and prevent some
relevant obstetrics complications. According to a recent
systematic review of the randomized studies on vitamin D
supplementation, the compound increases mean birth
weight of 58.33 g (95%CI 18.88–97.78 g) [24]. Moreover, a
lower risk in pre-eclampsia was observed in those women
receiving vitamin D supplementation, especially if they
received also calcium [25].
Some limitations of our study should be acknowledged.
Firstly, it has to be pointed out that the decision for a
single dose of 600.000 IU is a pragmatic choice and re-
markably simplifies our study design. Moreover, if signifi-
cant benefits will emerge, this modality could easily enter
clinical practice (considering also the low costs) and a high
adherence can be expected. On the other hand, a non-
significant result will not be a definitive reason to abandon
the studies on vitamin D supplementation prior to IVF
because one could argue that a more steady and constant
administration (such as 2.000 IU daily) could be more
beneficial. Secondly, the duration of vitamin D supple-
mentation prior to IVF can be an additional reason of
concern, in particular considering that we allowed for a
certain variability between Vitamin D administration and
the initiation of the cycle (2–12 weeks). In fact, folliculo-
genesis has been claimed to last 5–6months and our
protocol does not allow us to entirely cover this long
period. Our protocol actually consents to properly test the
effects of vitamin D on endometrial growth (a menstrual
flow will systematically occur after the administration)
and on final follicular growth (from dominance to ovula-
tion) but not on the full folliculogenesis process. Again,
we decided to privilege pragmatism and simplicity with
the aim of facilitating future clinical use but, again, we
have to admit that this choice can expose our results to
some criticisms if no significant difference will emerge.
Thirdly, we will request recruited women to avoid vitamin
D consumption but we cannot request them to avoid sun
exposure during the whole period of the IVF cycle. Even if
one has to expect a similar frequency of this situation in
the two study arms, this potential confounder might partly
dilute the potential benefits of the tested supplementation
of vitamin D. On the other hand, again, we opted for a
pragmatic study and this confounder would just reflect
real life situations. Fourthly, the decision to focus on
women with insufficient vitamin D (< 30 ng/ml) rather
than deficient (< 20 ng/ml) or even severely deficient (<
10 ng/ml) could be argued. In fact, the study will be
underpowered for a reliable subgroup analysis according
to the magnitude of the deficiency. In other words, we will
not be able to assess whether the intervention could be of
value only in a selected group (in particular those with the
lowest levels) rather than for the whole heterogeneous
group of women with serum levels below 30 ng/ml.
Fifthly, the decision to randomize even women with
serum levels below 10 ng/ml could be ethically debatable
because this is a condition of possible clinical relevance
per se. However, it has to be underlined that there is cur-
rently no recommendation for vitamin D testing before
IVF and, for this reason, we did not deem unethical to
include all women with serum levels below 30 ng/ml.
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Overall, despite the above-mentioned limitations of
our study design, we believe that this RCT could provide
clinically relevant findings, in particular if statistically
significant differences in favour of the treatment arm
will emerge. In fact, it can influence clinical practice.
High doses supplementation with vitamin D is an ex-
tremely simple and safe intervention and, if a significant
benefit will emerge, one has to expect a rapid and global
spread of its use. In addition, given the low costs of the
intervention (less than 10 € in Italy), the economical
profile can be expected to be highly cost-effective. On
the other hand, for the above-mentioned intrinsic limita-
tions consequent to our pragmatic choices, we have to
recognize that a negative finding will not definitely close
the issue.
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